{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.18","value":"1.8"},{"groupId":"OG001","spread":"30.75","value":"3.0"},{"groupId":"OG002","spread":"26.34","value":"7.4"}]}],"title":"Cycle 4 - approximately Month 4 (n=119,127,130)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.57","value":"5.7"},{"groupId":"OG001","spread":"32.42","value":"8.0"},{"groupId":"OG002","spread":"31.16","value":"6.9"}]}],"title":"Cycle 7 - approximately Month 7 (n=99,112,113)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.76","value":"9.3"},{"groupId":"OG001","spread":"36.29","value":"7.5"},{"groupId":"OG002","spread":"31.29","value":"5.6"}]}],"title":"Cycle 10 - approximately Month 10 (n=86,95,95)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.36","value":"9.7"},{"groupId":"OG001","spread":"33.42","value":"11.7"},{"groupId":"OG002","spread":"30.68","value":"5.7"}]}],"title":"Cycle 13 - approximately Month 13 (n=74,74,82)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.09","value":"12.2"},{"groupId":"OG001","spread":"34.22","value":"8.5"},{"groupId":"OG002","spread":"31.93","value":"7.1"}]}],"title":"Cycle 16 - approximately Month 16 (n=64,53,63)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning.","dispersionType":"Standard Deviation","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"MEAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Baseline (Day 0), Months 4, 7, 10, 13, 16","title":"Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale","type":"SECONDARY","unitOfMeasure":"units on a scale"}